<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:_2="http://www.w3.org/1999/xhtml"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2026-08-25</startDate>
            <endDate>2026-08-25</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-25</startDate>
            <endDate>2026-08-25</endDate>
        </period>
    </context>
    <unit id="securities">
        <measure>_2:securities</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-18">0001077183</dei:EntityCentralIndexKey>
    <ffd:FeeExhibitTp contextRef="c-1" id="f-19">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:SubmissnTp contextRef="c-1" id="f-1">S-8</ffd:SubmissnTp>
    <ffd:FormTp contextRef="c-1" id="f-2">S-8</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">NeoGenomics, Inc.</dei:EntityRegistrantName>
    <ffd:OfferingSctyTp contextRef="c-2" id="f-4">Equity</ffd:OfferingSctyTp>
    <ffd:PrevslyPdFlg contextRef="c-2" id="f-5">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTitl contextRef="c-2" id="f-6">Common Stock, $0.001 par value per share, reserved for issuance under the NeoGenomics, Inc. 2023 Equity Incentive Plan</ffd:OfferingSctyTitl>
    <ffd:Rule457aFlg contextRef="c-2" id="f-7">true</ffd:Rule457aFlg>
    <ffd:AmtSctiesRegd contextRef="c-2" decimals="0" id="f-8" unitRef="securities">5000000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty contextRef="c-2" decimals="2" id="f-9" unitRef="usd">16.65</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric contextRef="c-2" decimals="0" id="f-10" unitRef="usd">83250000</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate contextRef="c-2" decimals="7" id="f-11" unitRef="number">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt contextRef="c-2" decimals="2" id="f-12" unitRef="usd">11496.83</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="c-1" decimals="0" id="f-13" unitRef="usd">83250000</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="c-1" decimals="2" id="f-14" unitRef="usd">11496.83</ffd:TtlFeeAmt>
    <ffd:TtlOffsetAmt contextRef="c-1" decimals="2" id="f-15" unitRef="usd">0</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="c-1" decimals="2" id="f-16" unitRef="usd">11496.83</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="c-2" id="f-17">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In accordance with Rule 416(a) under the Securities Act of 1933, as amended (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Securities Act&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x201d;), this registration statement on Form S-8 (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Registration Statement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x201d;) shall be deemed to cover any additional shares of Common Stock, $0.001 par value per share (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x201d;) of NeoGenomics, Inc. (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x201d;) that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant&#x2019;s Common Stock, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated in accordance with Rules 457(c) and 457(h) of the Securities Act based upon the average of the high and low sale prices of the Common Stock as reported on the Nasdaq Global Market on August 21, 2026.&lt;/span&gt;</ffd:OfferingNote>
</xbrl>
